Botanix Pharmaceuticals (ASX:BOT) said it is unlikely to be affected by a proposed US executive order that would tie US drug prices to the lowest price paid by any other country globally, according to a Monday filing with the Australian bourse.
The company confirmed that its topical gel to treat excessive underarm sweating, Sofdra, is marketed exclusively in the US and is not sold in any other countries, the filing said.
Botanix added that it will review the proposed order when available.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.